ARV-6723 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10,252 results for “ARV-6723”

Trials

View all 9049 →

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

499 participants · First posted Aug 6, 2026

ARV Concentrations in Hair

84 participants · First posted May 11, 2016

Active, not recruiting

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

76 participants · First posted Jun 17, 2025

Drugs

View all 818 →

ARV-771

ARV-102

ARV-1802

Organizations

View all 23 →

Arvinas

United States

ARS PHARMACEUTICALS

India

ARx, LLC

United States

News

View all 362 →

Arvinas doses first patient with oral HPK1 PROTAC degrader ARV-6723 in advanced solid tumors

Bavdegalutamide (ARV-110) Shows Promise as AR Degrader in Preclinical Prostate Cancer Models

Arvinas Reports Promising Preclinical Data for ARV-393 and Glofitamab Combination in B-Cell Lymphoma

Page 1 of 1026